[HTML][HTML] SARS-CoV-2 infection and dysregulation of nuclear factor erythroid-2-related factor 2 (Nrf2) pathway
Abstract Coronavirus disease 2019 (COVID-19) is a recent pandemic caused by a novel
severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) leading to pulmonary and …
severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) leading to pulmonary and …
[HTML][HTML] COVID-19 and cardiovascular complications–preliminary results of the LATE-COVID study
J Lewek, I Jatczak-Pawlik, M Maciejewski… - Archives of Medical …, 2021 - ncbi.nlm.nih.gov
Methods We analysed consecutive patients (n= 51) admitted to the cardiology department
between 1 st October 2020 and 31 st January 2021 due to symptoms which might have …
between 1 st October 2020 and 31 st January 2021 due to symptoms which might have …
A comprehensive review on sarilumab in COVID-19
S Khiali, A Rezagholizadeh… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction: The coronavirus disease 2019 (COVID-19) pandemic, caused by a newly
discovered coronavirus (severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2) …
discovered coronavirus (severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2) …
[HTML][HTML] COVID-19: molecular and cellular response
In late December 2019, a vtiral pneumonia with an unknown agent was reported in Wuhan,
China. A novel coronavirus was identified as the causative agent. Because of the human-to …
China. A novel coronavirus was identified as the causative agent. Because of the human-to …
Acute viral illnesses and ischemic stroke: pathophysiological considerations in the era of the COVID-19 pandemic
MN Bahouth, A Venkatesan - Stroke, 2021 - Am Heart Assoc
The severe acute respiratory syndrome coronavirus 2 or coronavirus disease 2019 (COVID-
19) pandemic has raised concerns about the correlation with this viral illness and increased …
19) pandemic has raised concerns about the correlation with this viral illness and increased …
[HTML][HTML] Pathophysiological effects of SARS-CoV-2 infection on the cardiovascular system and its clinical manifestations—a mini review
JC Yugar-Toledo, LBT Yugar… - Frontiers in …, 2023 - frontiersin.org
Coronavirus disease 2019 (COVID-19) is a viral infection caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 may have a mild …
respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 may have a mild …
The Important Role of Interleukin‐2 in COVID‐19
L Ghanbari Naeini, L Abbasi, F Karimi… - Journal of …, 2023 - Wiley Online Library
There is controversial literature about the effects of the interleukin‐2 (IL‐2) cytokine family in
COVID‐19 pathogenesis and immunity. So we aimed to identify the potential in the role of …
COVID‐19 pathogenesis and immunity. So we aimed to identify the potential in the role of …
[HTML][HTML] Generalidades, aspectos clínicos y de prevención sobre COVID-19: México y Latinoamérica
RM Wong Chew, JA Morales Fernández - Universitas Medica, 2021 - scielo.org.co
El SARS-CoV-2 es un coronavirus, identificado por primera vez a finales del 2019 en
Wuhan (China) en personas con neumonía severa, que se propagó alrededor del mundo …
Wuhan (China) en personas con neumonía severa, que se propagó alrededor del mundo …
[HTML][HTML] Recommendations and guidelines for the diagnosis and management of Coronavirus Disease-19 (COVID-19) associated bacterial and fungal infections in …
HY Wu, PH Chang, YS Huang, CS Tsai… - Journal of Microbiology …, 2023 - Elsevier
Abstract Coronavirus disease-19 (COVID-19) is an emerging infectious disease caused by
SARS-CoV-2 that has rapidly evolved into a pandemic to cause over 600 million infections …
SARS-CoV-2 that has rapidly evolved into a pandemic to cause over 600 million infections …
[HTML][HTML] Aripiprazole as a candidate treatment of COVID-19 identified through genomic analysis
B Crespo-Facorro, M Ruiz-Veguilla… - Frontiers in …, 2021 - frontiersin.org
Background: Antipsychotics modulate expression of inflammatory cytokines and inducible
inflammatory enzymes. Elopiprazole (a phenylpiperazine antipsychotic drug in phase 1) has …
inflammatory enzymes. Elopiprazole (a phenylpiperazine antipsychotic drug in phase 1) has …